Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Background Respiratory syncytial virus (RSV), a major cause of illness and death in infants
worldwide, could be prevented by vaccination during pregnancy. The efficacy …

Viral bronchiolitis is the most common cause of admission to hospital for infants in high-
income countries. Respiratory syncytial virus accounts for 60–80% of bronchiolitis …

Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy …

Background Additional interventions are needed to reduce the morbidity and mortality
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …

Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion
conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in …